{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:03:23Z","timestamp":1792490603983,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7658","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2017,6,15]]},"DOI":"10.1038\/nature22337","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T05:01:53Z","timestamp":1496206913000},"page":"376-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":201,"title":["A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis"],"prefix":"10.1038","volume":"546","author":[{"given":"Ujjini H.","family":"Manjunatha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiti","family":"Vinayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Zambriski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislain M. C.","family":"Bonamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder R.","family":"Kondreddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gedeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie F.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian T.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sateriale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Tandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh B.","family":"Lakshminarayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siau H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bodenreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Joel","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Striepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry T.","family":"Diagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"BFnature22337_CR1","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","volume":"388","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000\u201315: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 388, 3027\u20133035 (2016)","journal-title":"Lancet"},{"key":"BFnature22337_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","volume":"382","author":"KL Kotloff","year":"2013","unstructured":"Kotloff, K. L. et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209\u2013222 (2013)","journal-title":"Lancet"},{"key":"BFnature22337_CR3","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/S2214-109X(15)00151-5","volume":"3","author":"JA Platts-Mills","year":"2015","unstructured":"Platts-Mills, J. A . et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob. Health 3, e564\u2013e575 (2015)","journal-title":"Lancet Glob. Health"},{"key":"BFnature22337_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley, W. et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect. Dis. 15, 85\u201394 (2015)","journal-title":"Lancet Infect. Dis."},{"key":"BFnature22337_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2334-9-195","volume":"9","author":"B Amadi","year":"2009","unstructured":"Amadi, B. et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect. Dis. 9, 195 (2009)","journal-title":"BMC Infect. Dis."},{"key":"BFnature22337_CR6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","volume":"360","author":"B Amadi","year":"2002","unstructured":"Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375\u20131380 (2002)","journal-title":"Lancet"},{"key":"BFnature22337_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/503189a","volume":"503","author":"B Striepen","year":"2013","unstructured":"Striepen, B. Parasitic infections: time to tackle cryptosporidiosis. Nature 503, 189\u2013191 (2013)","journal-title":"Nature"},{"key":"BFnature22337_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature14651","volume":"523","author":"S Vinayak","year":"2015","unstructured":"Vinayak, S. et al. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 523, 477\u2013480 (2015)","journal-title":"Nature"},{"key":"BFnature22337_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1126\/science.1193225","volume":"329","author":"M Rottmann","year":"2010","unstructured":"Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175\u20131180 (2010)","journal-title":"Science"},{"key":"BFnature22337_CR10","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/cbic.201500472","volume":"16","author":"N B\u00fcrstner","year":"2015","unstructured":"B\u00fcrstner, N. et al. Gift from nature: cyclomarin A kills mycobacteria and malaria parasites by distinct modes of action. ChemBioChem 16, 2433\u20132436 (2015)","journal-title":"ChemBioChem"},{"key":"BFnature22337_CR11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.1211936","volume":"334","author":"S Meister","year":"2011","unstructured":"Meister, S. et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372\u20131377 (2011)","journal-title":"Science"},{"key":"BFnature22337_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature12782","volume":"504","author":"CW McNamara","year":"2013","unstructured":"McNamara, C. W. et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248\u2013253 (2013)","journal-title":"Nature"},{"key":"BFnature22337_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1021\/ml500244m","volume":"5","author":"B Zou","year":"2014","unstructured":"Zou, B. et al. Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. ACS Med. Chem. Lett. 5, 947\u2013950 (2014)","journal-title":"ACS Med. Chem. Lett."},{"key":"BFnature22337_CR14","unstructured":"Chatterjee, A. K. et al. Preparation of pyrazolopyridine compounds for the treatment of parasitic diseases. US patent WO 2014078802 A1 (2014)"},{"key":"BFnature22337_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.exppara.2009.03.018","volume":"124","author":"L Xiao","year":"2010","unstructured":"Xiao, L. Molecular epidemiology of cryptosporidiosis: an update. Exp. Parasitol. 124, 80\u201389 (2010)","journal-title":"Exp. Parasitol."},{"key":"BFnature22337_CR16","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1128\/AAC.03080-15","volume":"60","author":"AM Zeeman","year":"2016","unstructured":"Zeeman, A. M. et al. PI4 kinase is a prophylactic but not radical curative target in Plasmodium vivax-type malaria parasites. Antimicrob. Agents Chemother. 60, 2858\u20132863 (2016)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature22337_CR17","doi-asserted-by":"publisher","first-page":"P38","DOI":"10.1186\/1475-2875-13-S1-P38","volume":"13","author":"S Ghidelli-Disse","year":"2014","unstructured":"Ghidelli-Disse, S. et al. Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics. Malar. J. 13 (Suppl. 1), P38 (2014)","journal-title":"Malar. J."},{"key":"BFnature22337_CR18","doi-asserted-by":"publisher","first-page":"e0003987","DOI":"10.1371\/journal.pntd.0003987","volume":"9","author":"CD Huston","year":"2015","unstructured":"Huston, C. D. et al. A proposed target product profile and developmental cascade for new cryptosporidiosis treatments. PLoS Negl. Trop. Dis. 9, e0003987 (2015)","journal-title":"PLoS Negl. Trop. Dis."},{"key":"BFnature22337_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/acsinfecdis.6b00094","volume":"2","author":"UH Manjunatha","year":"2016","unstructured":"Manjunatha, U. H ., Chao, A. T ., Leong, F. J. & Diagana, T. T. Cryptosporidiosis drug discovery: opportunities and challenges. ACS Infect. Dis. 2, 530\u2013537 (2016)","journal-title":"ACS Infect. Dis."},{"key":"BFnature22337_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ab.2009.09.009","volume":"396","author":"BR Branchini","year":"2010","unstructured":"Branchini, B. R. et al. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal. Biochem. 396, 290\u2013297 (2010)","journal-title":"Anal. Biochem."},{"key":"BFnature22337_CR21","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1128\/AAC.42.8.1959","volume":"42","author":"CM Theodos","year":"1998","unstructured":"Theodos, C. M., Griffiths, J. K., D\u2019Onfro, J., Fairfield, A. & Tzipori, S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42, 1959\u20131965 (1998)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature22337_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00436-012-3258-2","volume":"112","author":"JA Zambriski","year":"2013","unstructured":"Zambriski, J. A. et al. Description of fecal shedding of Cryptosporidium parvum oocysts in experimentally challenged dairy calves. Parasitol. Res. 112, 1247\u20131254 (2013)","journal-title":"Parasitol. Res."},{"key":"BFnature22337_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.vetpar.2013.04.022","volume":"197","author":"JA Zambriski","year":"2013","unstructured":"Zambriski, J. A. et al. Cryptosporidium parvum: determination of ID50 and the dose-response relationship in experimentally challenged dairy calves. Vet. Parasitol. 197, 104\u2013112 (2013)","journal-title":"Vet. Parasitol."},{"key":"BFnature22337_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1645\/GE-2475.1","volume":"97","author":"ML Bellosa","year":"2011","unstructured":"Bellosa, M. L. et al. A comparison of fecal percent dry matter and number of Cryptosporidium parvum oocysts shed to observational fecal consistency scoring in dairy calves. J. Parasitol. 97, 349\u2013351 (2011)","journal-title":"J. Parasitol."},{"key":"BFnature22337_CR25","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1021\/jm3001373","volume":"55","author":"Y Younis","year":"2012","unstructured":"Younis, Y. et al. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J. Med. Chem. 55, 3479\u20133487 (2012)","journal-title":"J. Med. Chem."},{"key":"BFnature22337_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1086\/528374","volume":"197","author":"A Castellanos-Gonzalez","year":"2008","unstructured":"Castellanos-Gonzalez, A. et al. Cryptosporidium infection of human intestinal epithelial cells increases expression of osteoprotegerin: a novel mechanism for evasion of host defenses. J. Infect. Dis. 197, 916\u2013923 (2008)","journal-title":"J. Infect. Dis."},{"key":"BFnature22337_CR27","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1128\/AAC.02460-12","volume":"57","author":"K Bessoff","year":"2013","unstructured":"Bessoff, K., Sateriale, A., Lee, K. K. & Huston, C. D. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob. Agents Chemother. 57, 1804\u20131814 (2013)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature22337_CR28","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1371\/journal.pntd.0000794","volume":"4","author":"L Sharling","year":"2010","unstructured":"Sharling, L. et al. A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase. PLoS Negl. Trop. Dis. 4, e794 (2010)","journal-title":"PLoS Negl. Trop. Dis."},{"key":"BFnature22337_CR29","doi-asserted-by":"publisher","first-page":"269ra3","DOI":"10.1126\/scitranslmed.3010597","volume":"7","author":"UH Manjunatha","year":"2015","unstructured":"Manjunatha, U. H. et al. Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci. Transl. Med. 7, 269ra3 (2015)","journal-title":"Sci. Transl. Med."},{"key":"BFnature22337_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/17425255.2.6.823","volume":"2","author":"B Faller","year":"2006","unstructured":"Faller, B. et al. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis. Expert Opin. Drug Metab. Toxicol. 2, 823\u2013833 (2006)","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnature22337_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.2174\/138920008786485227","volume":"9","author":"B Faller","year":"2008","unstructured":"Faller, B. Artificial membrane assays to assess permeability. Curr. Drug Metab. 9, 886\u2013892 (2008)","journal-title":"Curr. Drug Metab."},{"key":"BFnature22337_CR32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1073\/pnas.70.3.782","volume":"70","author":"BN Ames","year":"1973","unstructured":"Ames, B. N., Lee, F. D. & Durston, W. E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl Acad. Sci. USA 70, 782\u2013786 (1973)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature22337_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1099\/jmm.0.2008\/001461-0","volume":"57","author":"N Jothikumar","year":"2008","unstructured":"Jothikumar, N., da Silva, A. J., Moura, I., Qvarnstrom, Y. & Hill, V. R. Detection and differentiation of Cryptosporidium hominis and Cryptosporidium parvum by dual TaqMan assays. J. Med. Microbiol. 57, 1099\u20131105 (2008)","journal-title":"J. Med. Microbiol."},{"key":"BFnature22337_CR34","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1128\/JCM.43.9.4551-4557.2005","volume":"43","author":"J Dreier","year":"2005","unstructured":"Dreier, J., St\u00f6rmer, M. & Kleesiek, K. Use of bacteriophage MS2 as an internal control in viral reverse transcription-PCR assays. J. Clin. Microbiol. 43, 4551\u20134557 (2005)","journal-title":"J. Clin. Microbiol."},{"key":"BFnature22337_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4269\/ajtmh.14-0488","volume":"92","author":"DJ Operario","year":"2015","unstructured":"Operario, D. J., Bristol, L. S., Liotta, J., Nydam, D. V. & Houpt, E. R. Correlation between diarrhea severity and oocyst count via quantitative PCR or fluorescence microscopy in experimental cryptosporidiosis in calves. Am. J. Trop. Med. Hyg. 92, 45\u201349 (2015)","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature22337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature22337","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nature22337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/nature22337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:48:14Z","timestamp":1733939294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature22337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":35,"journal-issue":{"issue":"7658","published-print":{"date-parts":[[2017,6,15]]}},"alternative-id":["BFnature22337"],"URL":"https:\/\/doi.org\/10.1038\/nature22337","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727678595.793549971","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.727678595.793536253","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"assertion":[{"value":"27 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.R.K. and B.Z. are named as inventors on a pyrazolopyridine patent application related to this work (WO 20140788002 A1). U.H.M. and T.T.D. are named as inventors on a pending cryptosporidiosis patent application related to this work. All Novartis Institute for Tropical Diseases-affiliated authors are employees of Novartis and some own shares in Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}